This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

NeoStem To Present At Multiple Conferences In January

Stocks in this article: NBS

NEW YORK, Jan. 2, 2013 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS) ("NeoStem" or the "Company"), an emerging leader in the fast growing cell therapy market, today announced that the Company and its subsidiary, Progenitor Cell Therapy ("PCT"), will present at multiple conferences in January.

Biotech Showcase TM 2013

  • Date: January 8, 2013, 4:15 PM PST
  • Venue: Parc 55 Wyndham, San Francisco – Union Square, San Francisco, CA
  • Speaker: Andrew L. Pecora, M.D., FACP, Chief Medical Officer and Director, NeoStem, will present on Amorcyte

Scale-Up and Manufacturing of Cell-Based Therapies II

  • Date: January 22, 2013, 4:50 PM PST
  • Venue: Hyatt Regency Mission Bay Spa and Marina, San Diego, CA
  • Session Title: Cell Therapy Facility Design
  • Speaker: Robert A. Preti, Ph.D., President and Chief Scientific Officer of PCT

Eighth International Conference on Cell Therapy for Cardiovascular Diseases (IC3D 2013)

  • Date: January 24, 2013, 9:30 AM EST
  • Venue: Vivian and Seymour Milstein Family Heart Center, New York City, NY
  • Session Title: AMR-001 Phase 1 Outcome and PreSERVE Study Design: Autologous CD34+ Cells
  • Speaker: Jonathan Sackner-Bernstein, M.D., FACC, Vice President of Clinical Development and Regulatory Affairs, NeoStem

Phacilitate's Cell & Gene Therapy Forum

  • Venue: The Grand Hyatt, Washington, DC
  • Session 1 --  Date: January 28, 2013, 10:40 AM EST --  Session Title: Industry and payer perspectives - What are the current issues that might prevent a cell or gene therapy product candidate from being commercially viable, and how can they be addressed? --  Panelist: Robert A. Preti, Ph.D., President and Chief Scientific Officer of PCT
  • Session 2 --  Date: January 28, 2013, 1:05 PM EST --  Session Title: How to optimize the financial and operational efficiency of an emerging cell therapy business? --  Speaker: Sanjin Zvonic, Ph.D., Director, Technology & Business Development, PCT
  • Session 3 --  Date: January 29, 2013, 3:05 PM EST --  Session Title: Product characterization as a cornerstone of a commercially successful cell therapy product --  Speaker: Timothy Fong, Ph.D., M.B.A., Vice President, Technology & Product Development, PCT

About NeoStem, Inc.

NeoStem, continues to develop and build on its core capabilities in cell therapy, capitalizing on the paradigm shift occurring in medicine. We anticipate that cell therapy will have a significant role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society. We are emerging as a technology and market leading company in this fast developing cell therapy industry. Our multi-faceted business strategy combines a state-of-the-art contract development and manufacturing subsidiary, PCT, with a medically important cell therapy product development program, enabling near and long-term revenue growth opportunities. We believe that, with our expertise and research capabilities and collaborations, we will achieve our mission of becoming a premier cell therapy company.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs